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Objectives. The objectives of this proof of concept study were to (a) examine the temporal changes in fatigue and diversity of the
gut microbiome over the course of chemoradiotherapy (CRT) in adults with rectal cancers; (b) investigate whether there are
diﬀerences in diversity of the gut microbiome between fatigued and nonfatigued participants at the middle and at the end of CRT;
and (c) investigate whether there are diﬀerences in the relative abundance of fecal microbiota at the phylum and genus levels
between fatigued and nonfatigued participants at the middle and at the end of CRT. Methods. Stool samples and symptom ratings
were collected prior to the inception of CRT, at the middle (after 12–16 treatments) and at the end (after 24–28 treatments) of the
CRT. Descriptive statistics and Mann–Whitney U test were computed for fatigue. Gut microbiome data were analyzed using the
QIIME2 software. Results. Participants (N � 29) ranged in age from 37 to 80 years. The median fatigue score signiﬁcantly changed
at the end of CRT (median � 23.0) compared with the median score before the initiation of CRT for the total sample
(median � 17.0; p ≤ 0.05). At the middle of CRT, the alpha diversity (abundance of Operational Taxonomic Units) was lower for
fatigued participants (149.30 ± 53.1) than for nonfatigued participants (189.15 ± 44.18, t(23) � 2.08, p ≤ 0.05). A similar trend was
observed for the Shannon and Faith diversity indexes at the middle of CRT. However, at the end of CRT, there were no signiﬁcant
diﬀerences for any alpha diversity indexes between fatigued and nonfatigued participants. Proteobacteria, Firmicutes, and
Bacteroidetes were the dominant phyla for fatigued participants, and Escherichia, Bacteroides, Faecalibacterium, and Oscillospira
were the most abundant genera for fatigued participants. Conclusion. CRT-associated perturbation of the gut microbiome
composition may contribute to fatigue.

1. Introduction
Locally advanced rectal cancer (RC) is treated with concomitant chemotherapy and radiation therapy (CRT) with
curative intent [1]. Standard RT is delivered ﬁve days a week
at doses of 1.8 Gy daily for a total of 50.4 Gy joined with

either continuous of 5-ﬂuorouracil (5-FU) over 5 days or
oral capecitabine 5 days per week for a total of 5 weeks.
Standard radiation therapy oncology group (RTOG) ﬁelds
are used, which encompass the rectum, regional nodes, and
pelvic small bowel. Although CRT has improved local
control of RC and survival, it often produces disruptive side
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eﬀects such as fatigue with negative impacts on health-related quality of life [2]. The etiology and associated mechanism of the cancer-related fatigue during CRT treatment
remain elusive [3]. There is some evidence, however, that
suggests that cancer treatment-induced gut microbial perturbation/dysbiosis (an imbalance in the intestinal microbiota or microorganism that live in the gut) contributes to
inﬂammation-enabling translocation of bacteria and
microbially-mediated metabolites into systemic circulation
and inducing aberrant activation of the immune system such
as cytokine-induced (i.e., interleukin-6) inﬂammatory reaction, which can aﬀect brain function and induce behavioral symptoms such as fatigue [4–8]. However, not enough
microbiomic studies exist to identify associations between
changes of the gut microbiota and fatigue severity during
CRT for RC. Fatigue phenotyping focused on gut microbiome perturbation can be a ﬁrst step towards a better
understanding of the biology of CRT-associated fatigue and
the development of personalized medicine/interventions to
target phenotype-based characteristics.
There is recent clinical evidence [9, 10] that RT or
chemotherapy can induce perturbation of the gut microbiome diversity and composition as seen in mice studies
[9, 11]. A study (n � 9) in gynecological cancer patients
reported a signiﬁcant decrease in the Shannon diversity
index (bacterial species diversity) through the pelvic RT
treatment [12]. In addition, they reported that during RT,
the phylum Fusobacterium signiﬁcantly increased, while the
phylum Firmicutes decreased compared with before RT. One
animal study (using real-time PCR to quantify bacteria)
showed that 5-FU chemotherapy is associated with a decrease in Clostridium spp., Lactobacillus spp., and Streptococcus spp. and an increase in Escherichia spp., as well as a
decrease of goblet cell numbers or mucus secretion in the
jejunum of rats [13]. The aforementioned evidence suggests
that patients undergoing chemotherapy or RT may exhibit
marked changes in their intestinal microbiota [4, 5, 9].
However, these studies focused on chemotherapy or RT, not
both, had heterogeneous groups and small sample sizes
suggesting that more research is needed regarding the
disruption of the intestinal microbiata during CRT.
Perturbation of the gut microbiota has been linked to
worsening of fatigue during pelvic RT [8, 14]. One small
cohort study found that fatigue symptoms were positively
correlated with the systemic markers of inﬂammation
(haptoglobin), and the microbial diversity, richness, and the
Firmicutes/Bacteroidetes ratio was signiﬁcantly altered prior
to pelvic RT in patients who later developed diarrhea with
signiﬁcant worsening in fatigue [14]. There is an emerging
interest in how CRT can play a part in decreased microbial
diversity and increased bloom of pathobionts to inﬂuence
systemic inﬂammatory responses with consequential behavioral eﬀects [4, 5, 8, 14]. This pilot study is aligned with
that interest. Therefore, the objectives of this proof of
concept study were to: (a) examine the temporal changes in
fatigue scores and in diversity of the gut microbiome over
the course of CRT of adults with RC; (b) investigate whether
there are diﬀerences in diversity of the gut microbiome
between fatigued and nonfatigued participants at the middle
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and at the end of CRT; and (c) investigate whether there are
diﬀerences in the relative abundance of fecal microbiota, at
the phylum and genus levels, between fatigued and nonfatigued participants at the middle and at the end of CRT.
Further research may point to a possible microbial signature
that can identify RC patients at risk to develop acute CRTrelated fatigue. Further, a better stratiﬁcation of at-risk
patients may optimize clinical care as well as improve quality
of life and health outcomes of patients and families.

2. Materials and Methods
2.1. Study Population. Newly diagnosed RC patients
scheduled to receive CRT were recruited for this study.
Exclusion criteria included progressive or unstable disease of
any body system causing clinically signiﬁcant fatigue;
documented history of major depression within the past 5
years; and uncorrected hypothyroidism or anemia. Patients
taking antibiotics, prebiotics, probiotics, steroids, and/or
immune-suppressant agents within one month prior to any
event of sample collection were also excluded. Data collection was conducted from September 2017 to April 2018.
The recruitment and data collection of study participants
took place at three ambulatory cancer treatment facilities:
two were in the southeastern United States, and one was in
San Juan, Puerto Rico. The Human Subjects Committees of
both the Southeastern Academic Medical Center and University of Puerto Rico Medical Science Campus approved the
study prior to data collection. All procedures performed in
studies involving human participants were in accordance
both with the ethical standards of the institutional and/or
national research committee and with the 1964 Helsinki
Declaration and its later amendments or comparable ethical
standards. Written informed consent was obtained from all
individual participants included in the study.
2.2. Demographics, Clinical Information, and Assessment of
Fatigue. After obtaining informed consent, participants
completed 2 paper forms: demographic information and the
7-item Patient-Reported Outcome Measures Information
System-fatigue (PROMIS-F). The forms were administered
before, at the middle (after 12 to 16 CRT treatments), and at
the end (after 24–28 treatments) of the CRT. The demographic form collected the respondent’s age, marital status,
occupational status, and education level. The principal investigator obtained the following clinical information from
the medical chart: stage of cancer, before treatment hemoglobin (Hgb) levels, prescribed and self-administered
medications, number of RT fractions, and total RT dose.
The 7-item, adult PROMIS-F form assesses the impact
and experience of fatigue in the past week [15]. For example,
one of the items reads “in the past seven days, how often did
you feel tired?” Each item was anchored by a 5-point Likerttype scale response (1 � never to 5 � always). Scores ranged
between 7 and 35 where high scores mean higher fatigue. A
total score was calculated by summing scores across items.
The 7-item PROMIS-F, Spanish and English versions have
been widely used to evaluate cancer-related fatigue and have
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well-documented validity and reliability [15–17]. The
PROMIS-F internal consistency in the present study was
0.90. Further, we compared the mean raw scores using the
recommended raw score meaningfully important diﬀerences
(MIDs) ranges for research in cancer patients which suggest
that raw-score MIDs estimates for the 7-item PROMIS-F are
in the range of 2-3 [17]. To optimize the fatigue phenotypic
characterization of the study participants, we grouped
participants for analysis based on a 3-point change in
PROMIS-F score from before to middle and from before to
end of CRT; fatigued participants were those with ≥3-point
increase in PROMIS-F score, and nonfatigued participants
were those with <3-point change in fatigue score.
2.3. Fecal Samples Collection. On the same day of the fatigue
assessment (before, at the middle, and at the end) of CRT,
each participant collected approximately 5 g of stool using a
sterile plastic container for each of the three study time
points. Participants stored the stool samples at their home
refrigerator and delivered them in person within 24 hr to the
research team. Aliquots of 250 mg of stool samples received
were immediately stored at − 80°C for approximately 30 days
before batch DNA extraction.
2.4. 16s RNA Gene Sequencing Microbiome Assay.
Extraction of DNA from stool bacteria (from stool samples
before (n � 29), at the middle (n � 26), and at the end (n � 22)
of CRT) for 16S RNA amplicon sequencing was conducted
following the Power Soil DNA Isolation kit (MoBio, Carlsbad,
CA) procedure and used as the template for PCR ampliﬁcation. The diﬀerences in number of stool samples at each
time point was due to either missing stool specimens or
antibiotics or probiotics being used at time of collection. DNA
concentrations were assessed by Qubit 3.0 Fluorometer (Life
Technologies; Thermo Scientiﬁc, Wilmington, DE). DNA
integrity was evaluated by loading 5 µl DNA on a 1% agarose
gel stained with ethidium bromide. Microbial sequencing was
performed on the MiSeq Illumina platform following the
Illumina protocol [18]. The V3/V4 region of the 16S bacterial
rDNA was ampliﬁed using the standard Illumina primers.
Reverse primers included a 12 base pairs (bp) nucleotide
barcode to facilitate multiplex sequencing of all 85 samples on
a single 300 bp paired-end MiSeq run (V3 kit). All reads that
passed the initial quality control were kept for further analyses, and the adapter and barcode sequences were removed.
Both read-ends were merged using a paired-end read merger
(PEAR) with a minimum overlap of 20 bp and a signiﬁcance
of 0.001 [19]. We obtained a total of 14,430,624 reads with an
average of 169,773 reads per sample.
The diversity measurements and microbial taxonomic
classiﬁcation were performed using Quantitative Insights
into Microbial Ecology (Qiime) version 2 software. Following the Qiime pipeline, high-quality Illumina reads were
trimmed and denoised using DADA2 [20], and then the
remaining sequences were aligned using Maﬀt [21]. A
phylogenetic tree was built to calculate metrics of Alpha
diversity: Shannon diversity index (accounts for both
abundance and evenness of the species present), number of
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observed Operational Taxonomic Units (OTUs), Pielou’s
evenness, and Faith phylogenetic diversity index (the estimators of microbial community evenness). In addition,
taxonomic classiﬁcation at the phylum and genus levels was
done with the qiime2 feature classiﬁer plugin using the
Greengenes 16S database and the ampliﬁcation primers used
to select the V3-V4 region. All diversity metrics and the
relative abundance were utilized to investigate eﬀects of CRT
on the gut microbiome and its association with fatigue.
2.5. Statistical Analysis. Descriptive statistics including the
frequency, percentages, means, and standard deviations (SDs)
were performed on demographics and disease characteristics of
the sample. In addition, descriptive statistics including the
means, SDs, and medians were computed for the PROMIS-F for
the sample as a whole and by fatigue group categories. Because
histograms showed that the PROMIS-F data were not normally
distributed, a nonparametric (Mann–Whitney U test) statistical
test was used to evaluate diﬀerences between before to middle
and between before to end of CRT. We used a Chi-squared test
or Spearman’s correlation to investigate the possible association
between fatigue and (a) infusion chemotherapy vs. oral chemotherapy, (b) stage, (c) gender, (d) age, (3) BMI (body mass
index), and (f) before treatment Hgb levels. The data were
analyzed using Statistics Package for Social Sciences SPSS,
version 24.0 for windows, and/or the R statistical software.
Normality of the gut microbiome variables (diversity and
relative abundance) was assessed using a Shapiro test with a
signiﬁcance threshold of p ≤ 0.05. We used mixed-eﬀects
regression analyses to investigate diﬀerences in the gut
microbiome diversity metrics over the course of the CRT
while adjusting for repeated measurements. We used a
double-tailed t-test or a Mann–Whitney U test with a signiﬁcance level of ≤0.05 to assess statistical diﬀerences between groups based on fatigue status at the middle and end
of CRT. To test whether microbiome variables (diversity and
taxonomy) before CRT could potentially predict fatigue
status after treatment, we used random forest classiﬁcation.
We assessed performance of classiﬁcation using balance
accuracy, deﬁned as the average between sensitivity (proportion of fatigue individuals correctly identiﬁed) and
speciﬁcity (proportion of nonfatigue individuals correctly
identiﬁed). Variable importance for classiﬁcation was
assessed using the mean decrease in the Gini index.

3. Results
3.1. Patient Characteristics. We approached 36 men and
women for possible participation in the study; 33 agreed to
participate, but only 29 were eligible and were consented. The
mean age of study participants was 61 years (SD 11.4); the large
majority was married or partnered (96%), well educated (85%),
and retired (69%). Most of the participants were male (nearly
61%) and non-Hispanic Whites (48%) followed by Hispanics
(30%). Table 1 describes the clinical characteristics of the
participants. Twenty participants had a clinical stage of T3
(69%), and 9 patients had stage 2 RC. Patients were treated with
the 3D technique with a standard protocol of 45 Gy in 25
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Table 1: Clinical characteristics of sample.

Variable

Mean

Age
Body mass index
Hemoglobin

61.00
27.19
13.96

SD

Range

N

Reference
range

11.40
37–80
29
4.16
15.5–38.0 26
1.17 12.20–17.70 22 11–18 g/dL

SD � standard deviation.

fractions to the pelvis, including the posterior pelvic nodes,
rectum, and mesorectum up to the L5-S1 disk space, and then a
6 to 8 Gy boost (51 to 53 Gy total) in 3 or 4 fractions to the
original tumor volume with a 1.5 cm margin. A total of 17
patients (53%) received concurrent continuous infusion of 5FU 225 mg/m2 over 24 hours, and 12 patients received oral
capecitabine 825 mg/m2 twice a day, 5 days per week for a total
of 5 weeks. Before treatment, Hgb levels were within reference
ranges (Table 1).
3.2. Severity of CRT-Related Fatigue. There were signiﬁcant
diﬀerences in severity of fatigue at the end of CRT (higher
scores indicate more severity) compared with the median
scores before the initiation of CRT (p ≤ 0.05) (Table 2). Half of
the participants were fatigued (n � 13; median fatigue � 19) at
the middle of the CRT, while half (n � 13; median
fatigue � 20) were in the nonfatigue group. Further, at the end
of the CRT, most participants were in the fatigue group
(n � 15; median fatigue � 24), and 7 were in the nonfatigue
group (median fatigue � 18). There were no statistical association between fatigue status and infusion chemotherapy vs.
oral chemotherapy neither at middle nor at end of treatment
(Chi-squared, p > 0.05). Similarly, there were no signiﬁcant
association between fatigue status and gender (p > 0.05) at
any time point. Furthermore, while there were no associations
between fatigue scores at any time point with either treatment,
age, BMI, number of treatment or before treatment Hgb levels
(p > 0.05), higher fatigue scores at before treatment
(rho � 0.50, p � 0.001) and at the middle of treatment
(rho � 0.45, p � 0.001) were associated with higher stage of
disease, respectively.
3.3. Temporal Changes in Diversity of the Gut Microbiome over
the Course of CRTfor the Total Sample Reads with an Average
of Reads per Sample. Table 3 shows the median values for each
computed alpha diversity indexes, namely, (a) Shannon’s diversity; (b) number of observed OTUs; and (c) the estimators
of community evenness (Faith and Pielou). Further comparison analysis for alpha diversity using the mixed-eﬀects regression analyses showed a signiﬁcantly lower Shannon’s
diversity at middle (p ≤ 0.03) and at the end of CRT (p < 0.01)
compared with before treatment for the whole sample
(Figure 1(a)). Similarly, a signiﬁcantly lower abundance of
OTUs at the middle (p ≤ 0.01) and at the end of treatment were
found (p ≤ 0.03) compared with the before treatment OTUs
(Figure 1(b)). There is also a trend towards lower Pielou’s
evenness index at the middle of CRT compared with before the
initiation of treatment (Figure 1(d)). There were no signiﬁcant
diﬀerences in any of the diversity indexes between those on

Table 2: Summary of Mann–Whitney U test for the PROMIS-F for
the total sample.
Pairs
Before vs.
Middle
Before vs.
End
Middle vs.
End
∗

Mann–Whitney
Median
U
17.0
307.5
20.0
17.0
218.5
23.0
20.0
253.5
23.0

p value
0.17
0.03∗
0.27

p ≤ 0.05.

Table 3: Medians for alpha diversity indexes before (n � 29), at the
middle (n � 26), and at the end (n � 22) of CRT.
Index
Observed
OTUS
Shannon
Faith
Pielou

Before
Median

Middle
Median

End
Median

190
6.11
21.14
0.82

176
5.90
18.70
0.80

134
5.58
14.52
0.81

The diﬀerences in number of samples at each time point were due to either
missing stool specimen or antibiotics or probiotic use at time of collection.

infusion of 5-FU vs. those on oral capecitabine at the middle
nor at the end of CRT, which suggests that both groups are
equivalent with respect to chemotherapy (S1. Table).
3.4. Diﬀerences in Alpha Diversity Indexes between Fatigued
and Nonfatigued Participants across Treatment. We compared the alpha diversity index proﬁles between fatigued and
nonfatigued participants at the middle and at the end of CRT.
Follow-up tests using Welch’s t-test showed signiﬁcant differences between fatigued and nonfatigued patients at the
middle of treatment (Figure 2(b)). More speciﬁcally, the mean
abundance of OTUs was lower for fatigued patients
(149.30 ± 53.1) than for nonfatigued patients (189.15 ± 44.18,
t(23) � 2.08, p ≤ 0.05). A similar trend was observed for the
Shannon and Faith diversity indexes at the middle of CRT
(Figures 2(a) and 2(c)). However, at the end of CRT, there
were no signiﬁcant diﬀerences for any alpha diversity indexes
between fatigued and nonfatigued patients, which is likely due
to the small sample size of this exploratory study (S2. Table).
3.5. Diﬀerences in Relative Abundance of Most Common
Phylum between Fatigued and Nonfatigued Participants across
Treatment. With taxonomic analysis, Firmicutes and Bacteroidetes were the two largest phyla for both the fatigued and
nonfatigued participants in the middle and at the end of CRT,
respectively (Table 4). In the middle of treatment, there is a
signiﬁcantly lower relative abundance of Bacteroidetes in
fatigued participants compared with nonfatigued participants
(U � 124, p ≤ 0.04) (Table 4). In the middle of the CRT, a
similar trend was observed in fatigued participants showing
an increase in Firmicutes/Bacteroidetes ratio compared with
nonfatigued participants. At the end of treatment, there is a
signiﬁcantly higher relative abundance of Bacteroidetes in
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p < 0.01

8
p = 0.03

400

p = 0.03
p < 0.01

p = 0.38

p = 0.04

300
Observed OTUs

Shannon diversity index

7

6

5

200

100

4

3
Before

Middle
Time point

After

Before

(a)

p = 0.74
p = 0.99
p = 0.73

p = 0.40
p = 0.08
p = 0.40

1.0
Pielou’s evenness index

Faith phylogenetic diversity

After

(b)

50

40

Middle
Time point

30

20

0.9

0.8

0.7

0.6

10

Before

Middle
Time point

After

(c)

Before

Middle
Time point

After

(d)

Figure 1: Alpha diversity indexes across time points of treatment (before (n � 29), middle (n � 26), and end (n � 22)) for all participants:
(a) Shannon, (b) observed OTUS, (c) Faith, and (d) Pielou.

fatigued participants compared with nonfatigued participants
(U � 16, p ≤ 0.01). There is also a trend towards a lower
abundance of Firmicutes/Bacteroidetes ratio and Firmicutes
among fatigued participants compared with nonfatigued
participants.
3.6. Diﬀerences in Relative Abundance of Selected Genera
between Fatigued and Nonfatigued Participants across
Treatment
3.6.1. Fecal Microbial Ecology of Fatigued Participants.
The fecal microbial composition between fatigued and
nonfatigued participants across treatment was also signiﬁcantly diﬀerent at the genus level (Figure 3). More specifically, we observed that at the middle of treatment, the
fatigued participants’ microbiota was signiﬁcantly enriched
from the Escherichia genus belonging to the phylum of

Proteobacteria compared with nonfatigued participants
(little to no representation of this genus) (p ≤ 0.05)
(Figure 3(d)). At the end of treatment, the fatigued participants’ microbiota was signiﬁcantly enriched from genera
Bacteroides (Figure 3(f )), which belong to the Bacteroidetes
phylum, and members of the Firmicutes phylum, including
the Faecalibacterium and the Oscillospira genera compared
with nonfatigued participants (p ≤ 0.05) (Figures 3(e) and
3(g)).
3.6.2. Fecal Microbial Ecology of Nonfatigued Participants.
At the middle of treatment, we observed that the nonfatigued participants’ microbiota was signiﬁcantly enriched
by a member belonging to the Verrucomicrobia phylum,
the Akkermansia genus (Figure 3(b)) and by members of
the Firmicutes phylum, including members of the Ruminococcaceae family, such as the Ruminococcus and the

6
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300
p = 0.06

p = 0.05
250
Observed OTUs

Shannon diversity index

7

6

5

200
150
100

4

50

No
Yes
Fatigue status at middle point

No
Yes
Fatigue status at middle point

(a)

(b)

0.95

0.95
p = 0.09

0.85
0.80
0.75
0.70

p = 0.23

0.90
Pielou’s evenness index

Faith phylogenetic diversity

0.90

0.85
0.80
0.75
0.70
0.65

0.65

0.60

0.60
No
Yes
Fatigue status at middle point

No
Yes
Fatigue status at middle point

(c)

(d)

Figure 2: Comparison of alpha diversity indexes at the middle of CRT for participants in each fatigue group (No � nonfatigued (n � 13);
Yes � fatigued (n � 13)): (a) Shannon, (b) observed OTUs, (c) Faith, and (d) Pielou.

Oscillospira genera (Figures 3(a) and 3(c)) compared with
the microbiota of fatigued participants (p ≤ 0.05). At the end
of treatment, we observed that the nonfatigued participants’
microbiota was signiﬁcantly enriched from members of the
Firmicutes phylum, including members of the Lactobacillaceae family such as Lactobacillus genus (p ≤ 0.05)
(Figure 3(h)).
3.6.3. Testing Whether Microbiome Variables (Diversity and
Taxonomy) before CRT Could Potentially Predict Fatigue
Status during CRT. We performed random forest classiﬁcation using the baseline microbiome variables as predictors
and fatigue status at the middle and at the end of treatment
separately as outcomes (Figure 4). Microbiome variables
included Shannon diversity index, OTUs, Pielou’s evenness
index, Faith phylogenetic diversity index, the 9 taxonomic

assignments at the phylum level (Proteobacteria, Actinobacteria, Bacteroidetes, Firmicutes, Verrucomicrobia, Fusobacteria, Tenericutes, TM7, and Synergistetes), and the
Firmicutes/Bacteroidetes ratio. At the middle point, we had
63% balanced accuracy in predicting participants with and
without fatigue with a sensitivity of 70% and speciﬁcity of
57%. At the end of treatment, we had 49% balanced accuracy
in predicting participants with and without fatigue with a
sensitivity of 73% and speciﬁcity of 25%.

4. Discussion
Our ﬁndings and discussion must be treated as preliminary
and should be interpreted with caution because of the
several limitations discussed below. Nonetheless, fatigue
often has been reported as one of the most distressing
symptoms that cancer patients face during treatment. In
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Table 4: Summary of Mann–Whitney U test for taxonomic analysis of relative abundance of four main bacterial phyla.
Phylum
Firmicutes/Bacteroidetes
Middle
End
Actinobacteria
Middle
End
Bacteroidetes
Middle
End
Firmicutes
Middle
End
Proteobacteria
Middle
End
∗

p ≤ 0.05 and

∗∗

Mann–Whitney U
p value

Fatigued
Median

Nonfatigued
Median

U

0.74
0.22

0.32
1.33

50
79

0.08
0.07

0.002
0.0008

0.002
0.0009

78
61

0.76
0.57

0.22
0.65

0.72
0.41

124
16

0.04∗
0.009∗∗

0.23
0.14

0.23
0.51

71
78

0.51
0.08

0.13
0.09

0.05
0.23

61
54

0.24
0.94

p ≤ 0.01 middle of treatment (fatigued n � 13; nonfatigued n � 13); end of treatment (fatigued n � 15; nonfatigued n � 7).

fact, evidence from cross-sectional studies suggests a
prevalence of severe fatigue in approximately 67% of patients during neoadjuvant CRT for nonmetastatic RC [22],
and 85% of patients complained of persistent fatigue postCRT [23]; however, limited longitudinal studies are available. The results of this exploratory study showed that fatigue worsened signiﬁcantly from before to the end of CRT
(p � 0.006 − 0.03). Similar ﬁndings have been reported
among head and neck cancer patients undergoing CRT [24].
Interestingly, we did not ﬁnd that fatigue was associated
with type of chemotherapy, gender, age, BMI, nor with
before treatment Hgb levels. These ﬁndings are consistent
with other reports in which neither gender and age nor total
dose of RT predicted fatigue severity during RT for patients
with diﬀerent cancer diagnoses [25]. Similarly, Gurren et al.
[26] showed that there was no correlation between fatigue
scores and Hgb levels during neoadjuvant RT for RC. The
contrary is found in a sample of advanced cancer patients
admitted for symptom control in which general fatigue was
correlated with Hgb levels [27]. Nonetheless, given the high
association of tumor stage with fatigue, clinicians need to be
aware of the possibility of worsening of fatigue among those
who present with higher tumor stage. These ﬁndings also
suggest the need for clinicians to continuously assess, plan,
and manage fatigue and other potential side eﬀects of CRT
in order to improve treatment outcomes in this understudied population [2]. A major gap in preventing and
managing CRT-induced fatigue is that its biological
mechanisms have not been identiﬁed. Nonetheless, renewed
interest in the gut-brain-axis and the notable advances in
high dimensional sequencing techniques/data have suggested a role of CRT-induced gut microbial perturbation/
dysbiosis in the pathobiology of CRT-related fatigue
[4, 5, 8, 9, 14]; however, comprehensive microbiomics
studies in this clinical population are scarce.
Our ﬁndings of this exploratory study suggest that
various factors such as CRT resulted in perturbation of the
gut microbiome composition. More speciﬁcally, gut

microbial perturbation in this study was characterized by
within-sample reduction in diversity in the middle and at the
end of CRT compared with before treatment for both the
Shannon diversity index and the observed species/OTUS.
Similar ﬁndings have been reported in patients undergoing
chemotherapy or pelvic RT alone. One study using 454 highthroughput pyrosequencing data found that both alpha
diversity indexes (Faith’s phylogenic diversity and observed
species) in 15 fecal samples collected after chemotherapy for
non-Hodgkin’s lymphoma were signiﬁcantly lower compared with samples collected before treatment [28]. Similarly, a small study (n � 11) among mixed pelvic cancer
patients, using 454 high-throughput pyrosequencing, found
a signiﬁcant decrease in the Shannon diversity index after
pelvic RT compared with before RT [14]. Interestingly, one
cross-sectional study compared the fecal microbiota of 33
healthy individuals, 17 colorectal cancer (CRC) patients
before treatment, 14 CRC patients treated with chemotherapy, and 5 CRC patients after surgery, but found no
signiﬁcant diﬀerences in alpha diversity indexes among
groups [29]. Nonetheless, our study ﬁndings suggest that the
global balance of bacterial populations in the gut changed in
response to genotoxic stress such as CRT.
Our investigation of the diversity of bacteria over time
revealed the novel ﬁnding that at the middle of CRT, the
observed OTUS diversity was lower among fatigued participants than nonfatigued participants. As previously highlighted, one pilot study suggested that gut microbiota
perturbation/dysbiosis might predict diarrhea and worsening
of fatigue in cancer patients receiving pelvic RT [14]. Other
authors have attempted to show a relationship between microbial diversity and behavioral symptoms in other fatiguing
conditions (e.g., myalgic encephalomyelitis/chronic fatigue
syndrome (ME/CFS)) [30]. For example, one study reported a
reduced diversity and altered composition of the gut
microbiome in individuals with ME/CFS compared with
healthy individuals [30]. Further longitudinal studies should
identify if decreased gut microbial diversity or time during
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Figure 3: Boxplots showing the relative abundance of selected genera between fatigued and nonfatigued groups (No/� nonfatigued;
Yes � fatigued) based on Mann–Whitney U test in fecal samples at the middle of treatment ((a) Ruminococcus, (b) Akkermansia,
(c) Oscillospira, and (d) Escherichia genus) and at the end of treatment ((e) Oscillospira, (f ) Bacteroides, (g) Faecalibacterium, and
(h) Lactobacillaceae) relative to baseline, pre-CRT. Middle of treatment (fatigued n � 13; nonfatigued n � 13); end of treatment (fatigued
n � 15; nonfatigued n � 7).

treatment are the most signiﬁcant drivers of CRT-associated
fatigue.
Our pilot taxa analysis results found that at the middle of
CRT, the majority of bacteria present in the gut of fatigued
participants was represented by Proteobacteria from the
Escherichia genera, which may include a potential pathogen
such as E. coli. E. coli and Salmonella commonly proliferate
in the blood cultures of hospitalized cancer patients with
fever [31]. Some strains of E. coli particularly in immunocompromised cancer patients have been linked to potentially
severe and life-threatening infections such as UTI [32], both
acute and chronic diarrhea (e.g., Enteropathogenic and
enterohaemorrhagic E. coli diarrhea [33], or bloodstream
infections) [34]. For example, one study (using real-time
PCR to quantify bacteria) observed that the microﬂora
composition of the majority of patients experiencing chemotherapy-induced diarrhea showed increase in E. coli and a
decrease in Lactobacillus spp. and Bacteroides spp. compared
with healthy voluntaries [33]. Also, some strains of E. coli are
positively correlated with CRC tumor size [35]. In addition,
some evidence suggests associations between E.coli and a
compromise intestinal barrier integrity, inﬂammation, and
potential hepatotoxic events in nonalcoholic fatty liver
disease [36]. This is remarkable because perhaps our data
support the hypothesis of a proinﬂammatory environment
in the fatigued group as evidenced by a signiﬁcantly higher
relative abundance of both the Bacteroidetes phylum and the
genera Bacteroides compared with the nonfatigued participants at the end of CRT. At the phylum level, increased
Bacteroidetes have been reported in intestinal inﬂammatory
conditions such as irritable bowel syndrome [37] and
nonalcoholic fatty liver disease [36]. Interestingly, the

Bacteroides genera may include a potential pathogen such as
the B. fragilis. In fact, a recent review of the literature
compiled information suggesting that enterotoxigenic
strains of B. fragilis have not only been associated with CRC
but also with bacteremia, colitis, diarrhea, sepsis, systemic
infection, systemic inﬂammation, and neurological diseases
such as Alzheimer’s disease [38]. This latter review also
highlighted that one of the mechanisms by which B. fragilis
can be associated with systemic inﬂammation and neurodegeneration may be related to the ability of B. fragilis to
secrete neurotoxins such as proinﬂammatory lipopolysaccharide BF-LPS. On the contrary, some strains of Faecalibacterium (which was also signiﬁcantly abundant among
fatigued participants) such as F. prausnitzii [39] and some
strains of Oscillospira [40] have been linked to anti-inﬂammatory properties.
We also demonstrated that at the middle of treatment,
the majority of bacteria present in the gut of nonfatigued
participants was represented by two distinct phyla: the
Verrucomicrobia phylum (Akkermansia genus, a beneﬁcial
microbe) and the Firmicutes phylum (Ruminococcus genera
and Oscillospira genera). This is important given that
Akkermansia has been reported to lead to anti-inﬂammatory
action in the intestinal tract and the enhancement of the
intestinal barrier function [41]. More speciﬁcally, it has been
suggested that A. muciniphila adheres to enterocytes and
strengthens the integrity of the epithelial cell layer, resulting
in a favorable intestinal immunity [42]. Further, butyrateproducing genera such as Oscillospira were detected among
both, nonfatigued participants at the middle of treatment
and fatigued participants at the end of treatment [40]. An
interesting fact is that animal studies have shown that
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Figure 4: Variable importance for classiﬁcation of fatigue status by random forest at the (a) middle of CRT and (b) end of CRT.

butyrate supplementation improves gut barrier function,
by attenuating inﬂammation and reducing endotoxin
levels [43]. It is noteworthy that our study also identiﬁed
that nonfatigued participants at the end of treatment
showed a Lactobacillus predominance in stool samples,
perhaps representing a period of clinical stability. The
order Lactobacillales includes species (e.g., Lactobacillus,
Lactococcus, and Enterococcus species) that have been
linked to the production of an acidic environment that
inhibits the growth of several species from harmful
bacteria [44]. Also, some strains in the genus Lactobacillus
(e.g., L. acidophilus, L. casei) have been found to have
probiotic properties [44], to ameliorate gut inﬂammation
[45], and to improve gut barrier function [46] in animal
models. On the contrary, the abundance of Oscillospira
and Ruminococcus has been linked to aging [47]. Notably,
comprehensive molecular analyses studies are needed to
conﬁrm and determine the role of a certain group of
bacteria in the etiology of CRT-associated fatigue and
other co-occurring symptoms (e.g., sleep disturbance,
depression, anxiety, pain, and cognitive impairment) as
well as in CRT-induced gastrointestinal symptoms (e.g.,
mucositis, nausea, and vomiting) [13, 33].
In contrast to our expectations, our preliminary study
found that gut microbial variables prior CRT have lower
accuracy in predicting fatigue during the acute phase of
treatment. This lower accuracy could be explained in part by
our moderate sample size. It may also be that other variables
that may have had a stronger association with fatigue (e.g.,
depression, albumin levels, inﬂammatory markers (e.g.,
haptoglobin, interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor2 levels), and uncontrolled
diarrhea, [14, 22, 27, 48]) were not included in the analysis.
Nonetheless, our study sets the stage for future validation
and optimization of the classiﬁer/model in a larger sample,
perhaps including a subgroup of healthy participants together with clinical data in a well-designed longitudinal
study. The ability to diﬀerentiate between patients with and

without fatigue symptoms or having a particular microbiome that may be risky for developing symptoms has
clinical relevance for the development of personalized
medicine/interventions.
4.1. Limitations. Limitations of this exploratory study include the use of fecal samples and not intestine contents.
However, fecal samples are commonly used to study
microbial communities [49], perhaps because these samples are easy to obtain from individuals compared with
intestinal tissue samples. Another limitation of this study
is the relatively moderate sample size; a larger sample size
would have permitted examining other variables of interest. For example, there may be other side eﬀects/variables caused by the cytotoxic eﬀects of CRT (e.g., anemia,
nutritional status [50], gastrointestinal disturbances
(mucositis, diarrhea and constipation; [39]), or external
factors (e.g., diet; [51]) that account for variance in both
the composition and diversity of gastrointestinal bacterial
populations that may inﬂuence the fatigue experience that
were not included in the analysis; however, collection of
data on those variables is currently ongoing. Longer
longitudinal studies examining persistent fatigue and
dysbiosis are needed to validate previous studies showing
that after the end of chemotherapeutic administration; the
bacterial abundance recovered within a few days, sometimes even with numbers elevating above initial levels [39].
These ﬁndings could provide information regarding
therapeutic eﬀorts to ameliorate both fatigue and gut
microbiota perturbation during the acute phase of treatment. In the context of RC, another limitation of this study
was not having data on contributing factors, such as tumor
characteristics (e.g., location and size [49]) or surgical
recovery (e.g., ischemia/reperfusion [52]) which can inﬂuence the gut microbiome and the tumor microenvironment, in addition to other concomitant treatments
(e.g., CRT).
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5. Conclusions
In our pilot study, we were able to extend the knowledge
about gut microbiota perturbation overtime during the
course of CRT and its relationship with fatigue in order to
provide a foundation for future mechanistic studies. Our
preliminary results showed that Proteobacteria, Firmicutes,
and Bacteroidetes were the dominant phyla for fatigued
participants, and Escherichia, Bacteroides, Faecalibacterium,
and Oscillospira were the most abundant genera for fatigued
participants. One of the possible routes for correcting
dysbiosis is by the administration of probiotics [44], which
might be part of our future research.
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